@article {BROWN335, author = {E. M. BROWN and M. F. ATTIE and S. REEN and D. G. GARDNER and J. KEBABIAN and G. D. AURBACH}, title = {Characterization of Dopaminergic Receptors in Dispersed Bovine Parathyroid Cells}, volume = {18}, number = {3}, pages = {335--340}, year = {1980}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {Several dopaminergic ligands were assessed for their effects on cAMP accumulation, adenylate cyclase activity, and parathyroid hormone (PTH) release from dispersed bovine parathyroid cells. Dopamine, 6,7-dihydroxy-1,2,3,4 tetrahydronaphthalene (ADTN), 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (SKF-38393), and apomorphine increased cAMP content 30-, 25-, 10-, and 2- to 3-fold with Ka{\textquoteright}s of 0.6, 0.5, 1, and 1-3 {\textmu}M, respectively. These same agents also stimulated adenylate cyclase activity up to 4-fold and PTH release 1.3- to 3-fold. With the exception of lisuride (Ki = 15 nM), ergot derivatives were of relatively low potency (Ki{\textquoteright}s = 0.4-20 {\textmu}M) in inhibiting dopamine-stimulated cAMP accumulation. Similar Ki{\textquoteright}s were observed for effects on dopamine-stimulated adenylate cyclase activity and PTH release. Interactions of these ligands with the dopamine receptor could be clearly differentiated from effects of β-adrenergic or α-adrenergic receptors also known to modulate cAMP accumulation and secretion in this cell type. These results demonstrate the presence of a D-1 dopaminergic receptor on bovine parathyroid cells and document further the relationship in this receptor subclass between adenylate cyclase activity, cAMP accumulation, and a biologic response.}, issn = {0026-895X}, URL = {https://molpharm.aspetjournals.org/content/18/3/335}, eprint = {https://molpharm.aspetjournals.org/content/18/3/335.full.pdf}, journal = {Molecular Pharmacology} }